Indivior Pharmaceuticals Inc
NASDAQ:INDVDrug Manufacturers - Specialty & Generic
+$0.26 today
- Market cap
- $4.53B
- Beta
- 1.17
- P/E (TTM)
- 19.1
- EPS (TTM)
- $2.00
Volume 3.65M
Average 2.08M
INDV Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Indivior Pharmaceuticals IncNASDAQ: INDV
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $12M fell 42.9% year over year, behind the -32.3% change in trailing-twelve-month research & development. Sequentially, it fell 25.0% from the prior quarter. Over 3 fiscal years it compounded at +9.4% a year.
Context
- Research & development amounted to 7.8% of revenue in FY2025, down 1.2 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -42.9% toward the trailing-twelve-month pace of -32.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 97M USD
- Year-over-year change
- -9.3%
- 4-year CAGR
- +16.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 97M | -9.3% |
| FY2024 | 2024-12-31 | 107M | -7.8% |
| FY2023 | 2023-12-31 | 116M | +56.8% |
| FY2022 | 2022-12-31 | 74M | +42.3% |
| FY2021 | 2021-12-31 | 52M | — |
Research & Development vs competitors
How INDV compares with its peers on the latest reported figures
- INDV's LTM Jun 2026 research & development of $65M is the 3rd highest of the 4 companies compared; the peer median is $126.09M.
- Its year-over-year change of -32.3% is the lowest of 3, against a peer median of +33.9%.
- Research & development amounts to 4.9% of revenue for INDV, versus a peer median of 15.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $430.42M | +49.7% | +5.9% | 24.5% | |
| LTM Jun 2026 | $126.09M | +18.1% | +12.5% | 15.2% | |
INDVIndivior Pharmaceuticals Inc | LTM Jun 2026 | $65M | -32.3% | +9.4% | 4.9% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding INDV) | $126.09M | +33.9% | +9.2% | 15.2% | |
Competitors are the stored peer set for INDV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 791M | 901M | 1.09B | 1.19B | 1.24B |
| Cost of Revenue | 127M | 151M | 174M | 231M | 246M |
| Gross Profit | 664M | 750M | 919M | 957M | 993M |
| Gross Margin | 83.9% | 83.2% | 84.1% | 80.6% | 80.1% |
| Research & Development | 52M | 74M | 116M | 107M | 97M |
| Selling, General & Admin | 431M | 469M | 569M | 618M | 634M |
| Operating Expenses | 451M | 831M | 1.08B | 925M | 728M |
| Depreciation & Amortization | 22M | 16M | 15M | 28M | 20M |
| EBITDA | 238M | (46M) | (99M) | 83M | 304M |
| EBITDA Margin | 30.1% | -5.1% | -9.1% | 7.0% | 24.5% |
| Operating Income | 213M | (81M) | (156M) | 32M | 265M |
| Operating Margin | 26.9% | -9.0% | -14.3% | 2.7% | 21.4% |
| Interest Income | 4M | 19M | 43M | 23M | 22M |
| Interest Expense | 26M | 29M | 35M | 41M | 45M |
| Other Income / Expenses | (23M) | (8M) | 7M | (18M) | (26M) |
| Income Before Tax | 190M | (89M) | (149M) | 14M | 239M |
| Pre-Tax Margin | 24.0% | -9.9% | -13.6% | 1.2% | 19.3% |
| Income Tax Expense | (15M) | (44M) | (20M) | 11M | 29M |
| Net Income | 205M | (44M) | (129M) | 2M | 210M |
| Net Margin | 25.9% | -4.9% | -11.8% | 0.2% | 16.9% |
| EPS (Basic) | 1.38 | (0.37) | (0.94) | 0.02 | 1.68 |
| EPS (Diluted) | 1.31 | (0.37) | (0.91) | 0.02 | 1.64 |
| Weighted Avg Shares | 145.66M | 139.01M | 137.31M | 132M | 125M |
| Weighted Avg Shares (Diluted) | 154.23M | 139.01M | 141.8M | 133M | 128M |
Indivior Pharmaceuticals Inc
NASDAQ:INDV
Intrinsic Alpha fair value
Locked
Current Price
$36.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.